Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Lakewood-Amedex Biotherapeutics Inc. (LABT)

Lakewood-Amedex posts investor deck on Nu-3 gel for infected diabetic foot ulcers

Neutral Impact 2 of 5 other Written later

Lakewood-Amedex Biotherapeutics made a corporate investor presentation available on July 15, 2026, describing its Bisphosphocin compound platform and its lead program, Nu-3, a topical antimicrobial gel for infected diabetic foot ulcers. The filing contains no financial results, guidance, or new financing, and the deck states that Phase 2a clinical trial milestones run from 3Q26 through 4Q26/1Q27 for top-line results.

Key points

  • Investor deck dated July 15, 2026, furnished as Exhibit 99.1 under Regulation FD and not deemed filed under the Exchange Act.
  • Deck lists Phase 2a trial milestones: clinical trial commences and first patient first visit in 3Q26; clinical trial complete in 4Q26; top-line results expected 4Q26/1Q27.
  • Intellectual property: 71 issued and 30 pending patents, with key filings providing protection through 2038 and recent applications through 2044.

The filing

CompanyLakewood-Amedex Biotherapeutics Inc. (LABT)
Form8-K, current report
Filed with the SECJul 15, 2026, 4:15 PM ET
Accession number0001213900-26-078328

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.